Analysis of work satisfaction

There are many factors around us that change our satisfaction, motivation and decisions. We all spend much time at work during our lifes and that is why I want to do a research of working satisfaction. I will realize this research by using a list of questions and oral interview in a company that employs about 60 people. I will focus on factors - wage, working environment, interpersonal relations - and their impact on the satisfaction rate. Main goal of my work is to improve care of eployees by proposing a recommendation to management of the company that may lead to lower fluctuation of employees, more effective work and higher prosperity of the company

VEŘEJNÁ SPRÁVA V USA SE ZAMĚŘENÍM NA E-GOVERNMENT

Práce hodnotí úroveň elektronického governmentu (e-governmentu) ve Spojených státech amerických na místní úrovni. Následně metodou korelační analýzy zkoumá, které z vybraných místních charakteristik nejvíce ovlivňují přijetí iniciativ e-governmentu samosprávnými orgány. Úroveň e-governmentu je měřena hodnocením webových portálů vybraného vzorku 120 municipalit po celém území Spojených států amerických. Pozornost je věnována také občanské participaci a transparentnosti veřejné správy. S přihlédnutím k rozdílnostem ve veřejné správě mezi Spojenými státy a Českou republikou by mohla být práce využita jako inspirace při reformě veřejné správy v České republice a při zavádění egovernmentu do veřejné správy

VEŘEJNÁ SPRÁVA V USA SE ZAMĚŘENÍM NA E-GOVERNMENT

Práce hodnotí úroveň elektronického governmentu (e-governmentu) ve Spojených státech amerických na místní úrovni. Následně metodou korelační analýzy zkoumá, které z vybraných místních charakteristik nejvíce ovlivňují přijetí iniciativ e-governmentu samosprávnými orgány. Úroveň e-governmentu je měřena hodnocením webových portálů vybraného vzorku 120 municipalit po celém území Spojených států amerických. Pozornost je věnována také občanské participaci a transparentnosti veřejné správy. S přihlédnutím k rozdílnostem ve veřejné správě mezi Spojenými státy a Českou republikou by mohla být práce využita jako inspirace při reformě veřejné správy v České republice a při zavádění egovernmentu do veřejné správy

Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic

Abstract Introduction Psoriasis is a chronic, immune-mediated inflammatory skin disease. Despite the availability of several therapies, many patients affected by this disease remain untreated, do not have adequate response, or suffer from treatment-related toxic effects. It has been shown that the interleukin (IL)-17 pathway plays a key role in the immunopathogenesis of psoriasis. Brodalumab, the first human monoclonal IgG2 antibody that selectively binds to subunit A of the human IL-17 receptor, blocking interactions with a number of cytokines of the IL-17 family, has confirmed fast onset of action, high complete clearance rates, and sustained efficacy. Nevertheless, there is only a limited amount of published real-world evidence (RWE) data. Methods This was an open-label, multicenter, real-world, prospective, non-interventional, non-controlled (single-arm) observational study (LIBERO-CZ) assessing the management of moderate to severe psoriasis with brodalumab in daily practice for up to 52 weeks of treatment. Results Fifty-four patients (70.4% male, mean age 46.9 ± 13.4 years, weight 95.6 ± 22.7 kg, disease duration 18.6 ± 12.7 years) were enrolled and included in the final analysis. Forty-nine of the patients completed the study and five discontinued prematurely; 51.8% of all the enrolled patients were biologic-naïve. At baseline, 28% patients were classified as severe (psoriasis area severity index (PASI) ≥ 20). Overall, the mean PASI decreased by 15.6 from 16.1 (± 5.0) at baseline to 0.5 (± 1.2) at the last visit. The primary endpoint of an absolute PASI ≤ 3 at week 12 (as observed analysis) was achieved by 95.9% of patients. The static Physician’s Global Assessment (sPGA) success (defined as clear = 0 and almost clear = 1) at week 52 was achieved by 92.1% of patients. PASI 75, PASI 90, and PASI 100 were achieved by 98.0%, 87.8%, and 75.5% of patients, respectively, after approximately 52 weeks of treatment. The study also recorded very positive results concerning patient-reported outcomes. Conclusions LIBERO-CZ confirms the fast onset and high clearance rates of brodalumab in real life in both biologic-naïve and biologic-experienced patients

Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe

Introduction: The broad and sustained efficacy of apremilast for psoriasis has been demonstrated in randomized and real-world observational studies. Data from Central and Eastern Europe (CEE) are lacking. Moreover, apremilast use in this region is limited by country-specific reimbursement criteria. This is the first study to report data on the real-world use of apremilast in the region. Methods: APPRECIATE (NCT02740218) was an observational, retrospective, cross-sectional study assessing psoriasis patients 6 (± 1) months after apremilast treatment initiation. The study aimed to describe the characteristics of patients with psoriasis receiving apremilast, estimate treatment outcomes, including Psoriasis Area Severity Index (PASI), Body Surface Area (BSA), and Dermatology Life Quality Index (DLQI), and assess dermatologists' and patients' perspectives on treatment using questionnaires including the Patient Benefit Index (PBI). Adverse event reports were taken from the medical records. Results: Fifty patients (Croatia: 25; Czech Republic: 20; Slovenia: 5) were enrolled. In patients continuing apremilast at 6 (± 1) months, mean (± SD) PASI score was reduced from 16.2 ± 8.7 points at treatment initiation to 3.1 ± 5.2 at 6 (± 1) months; BSA from 11.9% ± 10.3% to 0.8% ± 0.9%; DLQI from 13.7 ± 7.4 points to 1.6 ± 3.2. PASI 75 was reached by 81% of patients. Physicians reported that the overall treatment success fulfilled their expectations in more than two thirds of patients (68%). At least three-quarters of patients reported apremilast had a quite or very high benefit on the needs they identified as being most important. Apremilast was well tolerated; no serious or fatal adverse events were identified. Conclusion: Apremilast was effective in reducing skin involvement and improving quality of life in CEE patients having severe disease. Treatment satisfaction among physicians and patients was very high. These data add to the growing body of evidence showing consistent effectiveness of apremilast across the continuum of psoriasis disease severity and manifestations